Cytos Biotechnology AG

DGAP-News: Cytos Biotechnology Ltd announces hosting of Investor & Analyst Day in NYC

EQS Group-News: Cytos Biotechnology AG / Key word(s): Research Update
Cytos Biotechnology Ltd announces hosting of Investor & Analyst Day in

17.10.2013 / 18:00


Cytos Biotechnology Ltd to host Investor and Analyst R&D Day in New York

Schlieren (Zurich), Switzerland, October 18, 2013 - Cytos Biotechnology Ltd
(SIX:CYTN) will host an Investor and Analyst R&D Day for institutional
investors and research analysts on

Christian Itin, Chairman and CEO as well as senior executives of Cytos will
present on Cytos' lead program CYT003, which is in clinical development for
the treatment of allergic asthma.

Expert medical and scientific leaders in the field of asthma clinical
research will be featured speakers at the meeting:

  - Thomas B. Casale, MD, Professor of Medicine, University of South
    Florida School of Medicine, Tampa, Florida

  - Kai-Michael Beeh, MD, Medical Director of insaf Respiratory Research
    Institute, Wiesbaden, Germany

A live webcast of the Investor and Analyst R&D Day can be accessed by
visiting the investor relations section of Cytos' website at:

Participant Dial-in numbers for conference call:

Participant Dial In (Toll Free):                          + 1-877-870-4263
Participant International Dial In:                        + 1-412-317-0790

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel: +41 44 733 46 46

US Investor enquiries
Susan A. Noonan
Tel: +1 (212) 966 3650

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
novel, first-in-class, immune modulator in Phase 2 clinical development as
a potential new treatment for asthma.

CYT003 has a novel mechanism of action that inhibits the immune response
that causes asthma, and may therefore be beneficial for the control of
asthma. In a successfully completed Phase 2a study, CYT003 was shown to
maintain asthma control and lung function in patients with persistent
allergic asthma, despite withdrawal of standard therapy with inhaled
corticosteroids. CYT003 has been shown to have a good safety and
tolerability profile in more than 450 individuals receiving the active
agent so far.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of
Technology (ETH) in Zurich. It is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements

This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements.  You are urged to consider
statements that include the words 'will' or 'expect' or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, including that CYT003
may not demonstrate safety or efficacy in clinical trials, that there may
be delays in development or that CYT003 may not receive marketing approval,
and that the Company relies on outside financing to meet capital
requirements, which may not be available under acceptable terms or at all.
Against the background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or

End of Corporate News

Additional features:


Document title: Cytos Analyst Day NYC_131018


17.10.2013 This Corporate News was distributed by EQS Schweiz AG. - news archive:

The issuer is responsible for the contents of the release.


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Freiverkehr in Berlin, München, Stuttgart; Frankfurt in
             Open Market ; SIX

End of News    EQS Group News-Service
235119 17.10.2013

Weitere Meldungen: Cytos Biotechnology AG

Das könnte Sie auch interessieren: